Article Versions Notes

Manna M, Brabant M, Greene R, Chamberlain MD, Kumar A, Alimohamed N, Brezden-Masley C. Canadian Expert Recommendations on Safety Overview and Toxicity Management Strategies for Sacituzumab Govitecan Based on Use in Metastatic Triple-Negative Breast Cancer. Current Oncology. 2024; 31(9):5694-5708. https://doi.org/10.3390/curroncol31090422

Manna, Mita, Michelle Brabant, Rowen Greene, Michael Dean Chamberlain, Aalok Kumar, Nimira Alimohamed, and Christine Brezden-Masley. 2024. "Canadian Expert Recommendations on Safety Overview and Toxicity Management Strategies for Sacituzumab Govitecan Based on Use in Metastatic Triple-Negative Breast Cancer" Current Oncology 31, no. 9: 5694-5708. https://doi.org/10.3390/curroncol31090422

Manna, M., Brabant, M., Greene, R., Chamberlain, M. D., Kumar, A., Alimohamed, N., & Brezden-Masley, C. (2024). Canadian Expert Recommendations on Safety Overview and Toxicity Management Strategies for Sacituzumab Govitecan Based on Use in Metastatic Triple-Negative Breast Cancer. Current Oncology, 31(9), 5694-5708. https://doi.org/10.3390/curroncol31090422